IL4 and asthma: IL-4 aids in directing naïve CD4+ Th cells towards a Th2 phenotype, while IL-13 enhances airway inflammation and remodeling [43]; dupilumab has dual inhibition of both IL-4 and IL-13 which demonstrates more beneficial effects in asthma therapy.